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Background: PPARγ is a member of the nuclear hormone receptor superfamily. It has been considered as a mediator
regulating metabolism, anti-inflammation, and pro-proliferation in the Vascular Smooth Muscle Cells (VSMCs).
Thiazolidinediones (TZDs), synthetic ligands of PPARγ, have anti-proliferative and pro-apoptotic effects on VSMCs, which
prevent the formation and progression of atherosclerosis and restenosis following percutaneous coronary intervention
(PCI). However, the underlying mechanism remains elusive. This present study therefore aimed to investigate the
signaling pathway by which pioglitazone, one of TZDs, inhibits proliferation and induces apoptosis of VSMCs.
Methods: The effects of pioglitazone on VSMC proliferation and apoptosis were studied. Cell proliferation was
determined using BrdU incorporation assay. Cell apoptosis was monitored with Hoechst and Annexin V staining. The
expression of caspases and cyclins was determined using real-time PCR and Western blot.
Results: Pioglitazone treatment and PPARγ overexpression inhibited proliferation and induced apoptosis of VSMCs,
whereas blocking by antagonist or silencing by siRNA of PPARγ significantly attenuated pioglitazone’s effect.
Furthermore, pioglitazone treatment or PPARγ overexpression increased caspase 3 and caspase 9 expression, and
decreased the expression of cyclin B1 and cyclin D1 in VSMCs.
Conclusions: Pioglitazone inhibits VSMCs proliferation and promotes apoptosis of VSMCs through a PPARγ signaling
pathway. Up-regulation of caspase 3 and down-regulation of cyclins mediates pioglitazone’s anti-proliferative and
pro-apoptotic effects. Our results imply that pioglitazone prevents the VSMCs proliferation via modulation of caspase
and cyclin signaling pathways in a PPARγ-dependent manner.
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Proliferation and apoptosis of the Vascular Smooth Muscle
Cells (VSMCs) play a key role in the development and
progression of the atherosclerosis and restenosis after
percutaneous coronary intervention (PCI) [1,2]. Several
signaling pathways are involved in the progression of
atherosclerosis and restenosis and the key players* Correspondence: wanjing320@aliyun.com
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unless otherwise stated.include peroxisome proliferators-activated receptor gamma
(PPARγ) [3], platelet-derived growth factors (PDGF) [4],
endothelin-1 (ET-1) [5], thrombin, fibroblast growth factor
(FGF) [6]. Activation and interplay of these molecules in-
duce the proliferation and migration of VSMCs, leading to
formation of artery plaque. Several drugs, such as pioglita-
zone, a synthetic ligand of PPARγ, have been developed to
treat and prevent the proliferation of VSMCs by targeting
individual factors of these pathways.
PPARγ is a member of the nuclear hormone receptor
superfamily [7]. It has been initially considered as a
mediator regulating glucose and lipid metabolism. Mored. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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endothelial cells (ECs), VSMCs, macrophages and cardi-
omyocytes. PPARγ has multiple functions, including
anti-inflammation and pro-proliferation in VSMCs [8].
Apoptosis is an important contributor to the formation
of atherosclerosis, especially in the process of restenosis
after PCI. PPARγ has anti-apoptotic effect herein by
modulation of caspase 3 [9].
Pioglitazone is commonly used as a primary anti-
diabetic drug. Previous studies have shown that pioglita-
zone was able to inhibit the proliferation and induce
apoptosis of VSMCs [10,11]. However, the underlying
mechanisms have not been well understood yet. Hence,
the aim of present study was to determine if pioglitazone
regulates cell cycle and caspase cascades, leading to an
inhibition in VSMCs proliferation.
Materials and methods
Cell culture and in vitro cell treatment
Human coronary artery smooth muscle cells (Lonza,
Basel Switzerland) were grown and maintained in SmGM-
2 media (Lonza, Basel Switzerland) supplemented with 2%
fetal calf serum, 10 ng/mL human epidermal growth fac-
tor, 1.0 mg/ml hydrocortisone, 12 mg/mL bovine brain ex-
tract, 50 mg/mL gentamicin, and 50 ng/mL amphotericin
B at 37°C in 5% CO2 atmosphere. The purity of each
VSMCs preparation in culture (>99%) was confirmed by
immunocytochemistry for α-smooth muscle actin. VSMCs
between passage 2 and 6 were used for following
experiments. VSMCs (1 × 106) were treated for 24 h in
medium containing vehicle (0.5% methyl cellulose),
10 uM pioglitazone or 1 uM GW9662, (Sigma). To
over-express PPARγ-1 in VSMCs, cells were transduced
with the recombinant adenovirus at titers of 100 MOI
for 24 hours. Wild type PPARγ-1 adenovirus (Ad-wt-
PPARγ) and mutation PPARγ-1 adenovirus were kind
gifts from Dr. Qinglin Yang (Morehouse School of Medi-
cine, Atlanta, USA). According to the principles of siRNA
design and the PPARγ gene sequence (GenBank Accession
No. NM_005037), the duplexes of specific siRNA sequences
5′-GTTCAAACACATCACCCCC-3′ was synthesized, non
targeting siRNA: 5′-GCATATTGTCTATGACCAACT-3′.
Adenoviral transduction of VSMCs
The resultant recombinant virusmids were transfected
into packaging cells HEK293 to generate recombinant
adenoviruses. The primary crude lysates of the recombin-
ant adenoviruses were prepared and purified by cesium
chloride gradient ultracentrifugation as viral stocks and ti-
trated using a standard plaque assay. VSMCs were seeded
at a density of 2 × 105 in one 6-cm dish in antibiotic-free
medium containing 10% serum before incubation with the
transduction reagent Oligofectamine (Invitrogen Carlsbad,
CA). One day later, cells were transduced with therecombinant adenovirus at titers of 100 MOI for
24 hours following the manufacturer’s protocols. For
co-transduction studies, attractene (Qiagen) was employed
as the transduction agent following the manufacturer’s
recommendations, and non-targeting siRNA was used as
experimental controls. During the final 24 hours of trans-
fection, cells were treated with either vehicle (0.5% methyl
cellulose) or pioglitazone (1 μM) [12].
BrdU cell proliferation assay
The cell proliferation assay was performed by measuring
5-Bromo-2′-deoxy-uridine (BrdU) (Roche Applied Sci-
ence, USA) incorporation into the newly synthesized
DNA of replicating cells. To determine cell proliferation,
VSMCs were plated in 96-well plates and allowed to
attach for 24 hours. Cells were then treated with 1 uM
Pioglitazone, 10 uM GW9662 or transduced with the
recombinant adenovirus for 24 hours. The cells were
loaded with BrdU in the last 4 hours of treatment. BrdU
incorporation was quantified by an immunofluorescence
assay kit (Roche Applied Science, USA) following manu-
facturer’s instructions. Three fields were chosen ran-
domly from various sections to ensure objectivity of
sampling. Digital images were acquired using a confocal
microscope. Each assay repeated three times. The total
100 cells from each field were counted, and BrdU posi-
tive cell and the ratio of BrdU positive cell versus 100
cells were calculated using a confocal microscope. Each
assay repeated three times.
Apoptosis of VSMCs detected by Hoechst staining
To evaluate morphologic changes of apoptotic VSMCs,
morphology and apoptosis assay were performed using
the Hoechst staining as described previously [9]. Briefly,
cells were seeded on chamber slides, treated with 1 uM
Pioglitazone, 10 uM GW9662 or transduced with the re-
combinant adenovirus for 24 h. Cells then were washed,
fixed and stained with Hoechst 33258 (Sigma, St. Louis,
MO). Dead cells and apoptotic bodies were identified by
condensed or fragmented nuclei using a Nikon confocal
microscope. The apoptotic scores were counted from
five randomly selected fields by direct counting 500 cells
in each sample using a blinded method [13]. The per-
centage of apoptotic cells was calculated as the number
of apoptotic cells divided by the number of total cells.
Measurement of apoptosis by flow cytometry
Apoptosis was measured using the FITC-Annexin V
Apoptosis Detection kit (BD Bioscience, San Diego, CA)
as described previously with modifications [14]. Briefly,
VSMCs were harvested, incubated and treated with
10 uM GW9662, 1 uM pioglitazone or transduced with
the recombinant adenovirus for 24 h. After cell treat-
ment, VSMCs were washed twice with cold PBS and
Figure 1 Validation of overexpression and silencing of PPARγ.
A. Overexpression and silencing of PPARγ in VSMCs. VSMCs were
transduced with Ad-mu-PPARγ, Ad-wt-PPARγ or Ad-siRNA-PPARγ,
respectively. Cell pellets collected from different groups as indicated were
probed against PPARγ and β-actin by Western blot. B. Quantification of
PPARγ. The levels of PPARγ from distinct groups in (A) were quantified
and normalized to the level of control. *P < 0.05, **P < 0.001. Each
experiment has been repeated three times.
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pH 7.4, 140 mM NaCl, 2.5 mM CaCl2) at a concentration
of 1 × 106 cells/ml. Then 1 × 105 cells in 100 μl binding
buffer were transferred to 5 ml tubes and stained with 5 μl
of FITC-Annexin V and 5 μl propidium iodide (PI). The
cells were gently mixed and incubated at room tem-
perature for 15 min. After washing the cells with 1× bind-
ing buffer to remove the excess FITC-Annexin V and PI,
the cells were analyzed on a FACScan flow cytometer,
which the wavelength of excitation and emission were
488 nm and 525 nm, respecrively. The data were analyzed
using CellQuest software.
Detection of active caspases 3/7, 8 and 9 in VSMCs
Caspases activities were measured using the Vybrant
FAM caspase 3/7, 8 and 9 Assay Kit (Molecular Probes,
Invitrogen) according to the manufacturer’s recommen-
dations after the incubation of cells with pioglitazone
(1uM), GW9662 (10uM), or transduced with the recom-
binant adenovirus for 24 h. The assay was performed on
a fluorescent inhibitor of caspases (FLICA) methodology.
The increase in the caspases activities was determined
by comparing these results with the level of the un-
treated control. Samples analyzed on a FACScan flow
cytometry with 488 nm excitation and green emission
for the FLICA-stained cells.
Western blot
After cell treatment, VSMCs were washed with phosphate-
buffered saline (PBS) and lysed in RIPA buffer (Biotech,
Shanghai, China). After one freeze/thaw cycle, lysates were
centrifuged. Protein concentration was determined by a
BCA protein assay (Biotech, Shanghai, China) using
bovine serum albumin as the standard. A quantity
amounting to 10 μg of protein sample was subjected to
SDS-polyacrylamide gel electrophoresis. Proteins were
then transferred to an ECL nitrocellulose membrane
(Millipore). Incubating the membrane in Superblock
(Pierce) for 1 h blocked nonspecific binding. Membranes
were then incubated overnight at 4°C in primary anti-
bodies, PPARγ1, Cyclin D1, Cyclin B1/cdc2 and β-actin
(AbCam: ab8924, ab95281, ab7959, ab1801). All primary
antibodies dilution was 1:1000 in each reaction. The blots
were washed three times with TBST buffer and then incu-
bated for 1 h at room temperature with anti-rabbit sec-
ondary antibody conjugated with horseradish peroxidase.
Western blot analysis was conducted according to stand-
ard procedures using Supersignal chemiluminescence
detection substrate (Pierce).
Real time RT-PCR
Total RNA was extracted from VSMCs using TRIZOL
reagent (Invitrogen, Carlsbad, CA, USA). cDNA was
synthesized from 0.5 μg of total RNA with superscriptorreverse transcriptase (Invitrogen, Carlsbad, CA, USA).




AAAC-3′; Cyclin B1/cdc2-reverse: 5′-GCAGCATCTTCT
TGGGCACACA-3′; Cyclin D1-forward: 5′-AGGCGGAG




PCR analysis was performed using SyBR-Green mix (Ap-
plied Biosystems, Carlsbad, CA) on a 7500 Real Time PCR
station (Applied Biosystems). The results for real-time
PCR were calculated as ratio target gene expression
(experimental/ control) and were expressed as fold change.
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SPSS 11.0 software was used to for data analysis. Data
were presented as mean ± SEM. Student’s t-test was em-
ployed to assess the statistical significance. P < 0.05 was
regarded as significant.
Results
Manipulation of PPARγ expression in VSMCs
The expression levels of PPARγ in VSMCs were evaluated
by Western blot after transduction with Adenovirus en-
coding wild type PPARγ (Ad-wt-PPARγ), mutant PPARγFigure 2 Pioglitazone induced proliferation of VSMC through PPARγ.
signaling pathway. VSMCs alone (control), transduced with Ad-vector, Ad-w
addition, VSMCs treated with pioglitazone (PIO) (1uM), wt-PPARγ-overexpre
VSMCs treated with PIO (Pio + siRNA) were harvested 24 h later after treatm
indicated groups were recorded by confocal microscopy (600x). BrdU posit
were less than those from control and vector alone groups. On the other h
and GW6992 alone induced the proliferation of VSMCs. The data is the rep
cells to total cells was quantified. The BrdU positive cell numbers and total
positive cell versus total cell numbers was calculated. **P < 0.01, *P < 0.05. E(Ad-mu-PPARγ), or siRNA against PPARγ (Ad-siRNA-
PPARγ). As shown in Figure 1, PPARγ protein levels were
significantly increased in cells transduced with Ad-wt-
PPARγ compared to Ad-mu-PPARγ (3.8 ± 0.57 vs. 1.09 ±
0.12, P < 0.05) (Figure 1B). On the other hand, silencing
PPARγ in VSMCs has been achieved by Ad-siRNA-
PPARγ comparing with Ad-wt-PPARγ was 0.34 ± 0.02 vs.
3.8 ± 0.57 (P < 0.001), and Ad-siRNA-PPARγ comparing
with Ad non targeting siRNA was 0.147 ± 0.03 vs. 0.2415 ±
0.15 (P < 0.05) (Figure 1B). The efficiency of overexpres-
sion and knockdown of PPARγ has been determined.A. Proliferation of VSMCs is regulated by pioglitazone through PPARγ
t-PPARγ, or siRNA-PPARγ were labeled with BrdU, respectively. In
ssing VSMCs treated with PIO (Pio + wt-PPARγ), and PPARγ silenced
ent followed by BrdU labeling. The BrdU positive VSMCs from
ive VSMCs cells from wt-PPARγ, PIO + wt-PPARγ, and PIO alone groups
and, the addition of PIO in the absence of PPARγ (PIO + siRNA-PPARγ)
resentative of three individual experiments. B. The ratio of BrdU positive
cell numbers from each field were counted and the ratio of BrdU
ach experiment has been repeated three times.
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signaling pathway
We initially investigated whether pioglitazone inhibits
proliferation of VSMCs. VSMCs were treated with
pioglitazone (PIO), and the cell proliferation was deter-
mined by BrdU assay 24 hours later. As shown in
Figure 2, a significant decrease in cell proliferation was
observed in the PIO treated group compared with
controls (0.051 ± 0.01 vs. 0.175 ± 0.031, P < 0.05).
We next determined if PPARγ pathway mediates pio-
glitazone’s anti-proliferative effect. VSMCs were treated
with GW9662, a potent antagonist of PPARγ. GW9662
treatment significantly enhanced VSMCs proliferation
(0.248 ± 0.054 vs. 0.175 ± 0.031, P < 0.05) (Figure 2).
Furthermore, PPARγ silenced VSMCs were treated with
pioglitazone. Interestingly, PPARγ silencing by siRNA in
VSMCs totally abolished the inhibitory effects of PIOFigure 3 Induction of chromatin condensation of VSMCs by piolitazo
VSMCs. VSMCs were seeded on top of coverslips and transfected with vect
transduced) were then treated with different drugs as shown followed by H
B. Quantification of condensed chromatin from apoptotic VSMCs. The numbe
condensed-chromatin positive cells was determined. **P < 0.001, *P < 0.01. Va
experiment has been repeated three times.(0.279 ± 0.009 vs. 0.051 ± 0.01, P < 0.001) (Figure 2). Our
results indicate that anti-proliferative effect of pioglita-
zone is mediated by PPARγ signaling pathway.Pioglitazone induced apoptosis in VSMCs
The viability of VSMCs was detected with chromatin
condensation under the fluorescence microscope. Pio-
glitazone treatment or PPARγ overexpression signifi-
cantly increased the numbers of condensed chromatin
positive cells (5.51 ± 2.14% vs. 3.21 ± 0.27%, P < 0.01; and
6.32 ± 1.47% vs. 3.21 ± 0.27%, P < 0.001, respectively), indi-
cating an increase in VSMC apoptosis by pioglitazone
treatment. In contrast, GW9662 and PPARγ silencing sig-
nificantly reduced cell numbers of undergoing apoptosis
(1.67 ± 0.15% vs. 3.21 ± 0.27%, P < 0.01, and 1.17 ± 0.16%
vs. 3.21 ± 0.27%, P < 0.001, respectively) (Figure 3).ne. A. Pioglitazone induced chromatin condensation in the nuclei of
or, wt-PPARγ, or siRNA-PPARγ, respectively. Cells (non-transduced and
oechst staining. Arrows indicate the nuclei with condensed chromatin.
rs of VSMCs from different treatments were counted. The percentage of
lues are presented as the mean ± SEM of three different fields. Each
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of VSMCs has been further confirmed using Annexin V
staining (Figure 4). The frequency of the Annexin V+/PI-
cell population, which represents early apoptotic cell
subset, has been indicated (Figure 4A). Pioglitazone
increased apoptosis (6.38 ± 1.78% vs. 3.42 ± 0.16%, P <
0.001) and GW9662 reduced apoptosis (2.03 ± 0.11% vs.
3.42 ± 0.16%, P < 0.01). Overexpression of PPARγ was
able to induce apoptosis of VSMCs (6.09 ± 0.12% vs.
3.58 ± 0.04%, P < 0.001). This effect was further enhanced
by the treatment of pioglitazone (7.05 ± 0.24 vs. 3.58 ±
0.04%, P < 0.001). Silencing PPARγ completely blocked the
induction of apoptosis mediated by Pioglitazone (Figure 4).
These results suggest that pioglitazone induced VSMCFigure 4 Pioglitazone induced apoptosis of VSMCs. A. Pioglitazone-trea
with vector, wt-PPARγ, or siRNA-PPARγ, respectively. Cells (non-transdued o
VSMCs from distinct groups were then harvested and subjected to Annexin
apoptotic cells from three independent experiments (B) was shown. The n
Values are presented as the mean ± SEM, n = 3. **P < 0.001, *P < 0.01.apoptosis is in a PPARγ dependent pathway (Figure 4),
which is in consistent with the results from BrdU staining
(Figure 3).
Pioglitazone treatment activates caspase3/7 and 8
Activated caspase 3/7 is a critical effector in the apoptosis
signal pathway. Caspase 8 is a factor related to the extrin-
sic pathway, and caspase 9 is a key member along with
intrinsic pathway. To further investigate whether activated
caspases were involved in anti-proliferative effect of pio-
glitazone, activities of caspase3/7, 8, 9 were measured in
PIO treated VSMCs. As shown in Figure 5, PIO treatment
resulted in significant increases in activated caspase 3/7
(121.67 ± 3.06%) and caspase 8 (151.2 ± 7.03%), but not inted VSMCs are inclined to apoptosis. Cultured VSMCs were transfected
r transduced) were then treated with different drugs as indicated.
V staining. The representative staining plots (A) and the frequency of
umbers indicate the frequency of the Annexin V+/PI- cell population.
Figure 5 Pioglitazone regulated activities of caspases. A. The
activity of the effector caspase3/7 was shown in the control,
GW9662, Pioglitazone, PIO + siRNA-PPARγ and PIO + wt-PPARγ
treated VSMCs, respectively. B. The activity of the initial caspase of
intrinsic pathway-caspase8 in different gr006Fups. C. The activity of
the initial caspase of extrinsic pathway-caspase9 in different groups.
**P< 0.001, ***P< 0.0001. The activity of different caspases is normalized
to the control (100%). Percentage is presented as the mean ± SEM of
triplicates. Each experiment has been repeated three times.
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PPARγ was overexpressed in VSMCs (137.76 ± 1.91%,
173.56 ± 13.12%). In contrast, GW9662 treatment resulted
in significant decreases in the activation of caspase 3/7
(20.67 ± 2.51%) and caspase 8 (42.27 ± 1.46%) (Figure 5).
Silencing PPARγ inhibited pioglitazone’s effect on the
activation of caspase 3/7 (10.67 ± 1.53%) and caspase 8
(24.67 ± 3.1%), but has no influence on caspase 9 activa-
tion (Figure 5). These results suggest that pioglitazone
activates the extrinsic, not the intrinsic pathway through a
PPARγ dependent pathway.
Effect of pioglitazone on cyclins in VSMCs
To address the possibility that the down-regulation of
cyclins in pioglitazone treated VSMCs resulted in the in-
hibition of cell proliferation, the effect of pioglitazone on
transcription and expression levels of cyclin B1 and D1
were examined by RT-PCR and Western blot. As shown
in Figure 6, pioglitazone treatment significantly down-regulated expression of cyclin B1 and cyclin D1 at both
mRNA (0.46 ± 0.08, 0.41 ± 0.11) and protein (0.75 ± 0.12,
0.54 ± 0.17) levels. In contrast, GW9662 up-regulated
the mRNA (2.73 ± 0.22, 1.49 ± 0.31) and protein (2.18 ±
0.25, 3.32 ± 0.72) levels of cyclin B1and cyclin D1. More-
over, PPARγ silencing completely abolished pioglita-
zone’s effect. These results suggest that cyclin pathway
may involve in anti-proliferative effect of pioglitazone.
Discussion
The restenosis after PCI has become one of the most
concerned issues worldwide [15]. The proliferation and
apoptosis of VSMCs play critical roles in this pathologic
process [16]. Thus, many therapeutic treatments focused
on preventing VSMC proliferation and inducing apop-
tosis in VSMCs. TZD is one of the most well studied
agents. TZDs are synthetic ligands of PPARγ, which is a
member of the nuclear hormone receptor super-family.
TZDs are primarily used as anti-diabetes drugs. TZD
has also been indicated to have an anti-proliferative
function in rat renal arteriolar smooth muscle cells [17].
Recently, given their anti-proliferative and pro-apoptotic
effect, TZDs have been considered as novel drugs to pre-
vent or even reverse the formation of atherosclerosis
and post-PCI restenosis. Importantly, TZDs do not in-
crease the risk of overall cardiovascular morbidity or
mortality in comparison with standard glucose-lowering
drugs [18,19], although there was the controversy that
TZDs might potentially lead to serious adverse cardio-
vascular effects, such as heart failure after treatment
with rosiglitazone for type 2 diabetes [20-22] . However,
the mechanisms by which TZDs regulate VSMC prolifer-
ation have not been determined.
Previous studies have shown that TZDs suppress the
expression of inflammatory molecules, including TNF
(tumor necrosis factor)-α, MCP (monocyte chemotactic
protein)-1, IL-1β and IL-6 in VSMCs [23,24]. Moreover,
recent studies have revealed that c-fos was involved in
PPARγ agonists- induced growth suppression in VSMCs,
and TZDs inhibited the expression of c-fos via the block-
ade of MAPK pathway [25]. Furthermore, Eukaryotic initi-
ation factor 4E-binding protein (4EBP) and Src homology
2–containing inositol phosphatase 2 (SHIP2) mediate the
inhibitory effects of TZD on cell growth [26]. Finally, it
has been shown that TZDs prevent G1/S phase transition
in PDGF or insulin stimulated VSMCs, suggesting that
TZDs can induce cell cycle arrest [27].
It has been known that TZDs have anti-proliferative
effect in different cell types via PI3-Kinase pathway [28].
However, whether this effect is PPARγ-dependent re-
mains to be clarified [29,30]. The effects of PPARγ in
the vascular cells indicate its beneficial function in vas-
cular disorders including hypertension and atheroscler-





Figure 6 Pioglitazone down-regulated the expression levels of the cyclin B1 and cyclin D1 in VSMCs. A, B, The protein levels of cyclin B1
and cyclin D1 from VSMCs treated with GW9662, Pioglitazone, PIO + wt-PPARγ, or PIO + siRNA-PPARγ were analyzed by Western blot, respectively.
C, D. The protein levels of cyclin B1 and cyclin D1 from VSMCs transduced with control, Ad-wt-PPARγ or Ad-siRNA-PPARγ were shown. One
representative blot is shown. Each experiment has been repeated at least three times. E and F, the mRNA levels of cyclin B1 and cyclin D1 in
VSMCs treated with GW9662, Pioglitazone, PIO + wt-PPARγ, or PIO + siRNA-PPARγ were analyzed by real-time RT-PCR. The transcripts of cyclin B1
and cyclin D1 were also determined in PPARγ-overexpressed or -silenced VSMCs. Values are presented as the mean ± SEM. *P < 0.01, **P < 0.001.
Each experiment has been repeated three times.
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PPARγ-mediated inhibition of ERK-dependent phos-
phorylation and activation of nuclear transcription fac-
tors. However, this group revealed that TZDs activated
MEK/ERK pathway through PI3-kinase and promoted
c-fos mRNA expression and DNA synthesis, a process
independent of PPARγ pathway [30]. Cersosimo group
suggested pioglitazone preserved Akt phosphorylation
and attenuates MAPK signaling in insulin-stimulated
VSMCs, and may play a role in arterial smooth muscle
cells migration, proliferation, and inflammation inconditions of acute hyperinsulinemia [32]. In our study,
we found that pioglitazone treatment and PPARγ over-
expression inhibited VSMC proliferation. Whereas silen-
cing PPARγ with siRNA attenuated the inhibitory
effects. These results clearly indicate that the PPARγ
signaling pathway is involved in anti-proliferative effect
of pioglitazone. Pioglitazone is already shown to inhibit
in-stent neointimal formation in humans [33].
Cyclins play critical roles in cell cycle regulation, espe-
cially cyclin B1 and cyclin D1 [34]. PPARγ ligands inhib-
ited G1 to S transition by inhibiting the expression of
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downstream effector factors of pRB/E2F pathway [35].
Stimulation of PPARγ induced the arrest of cell cycle,
accompanied by the down-regulation of cyclin D and
cyclin B in VSMCs [36-39]. To determine the detailed
mechanisms by which pioglitazone regulates VSMC pro-
liferation, in this study the mRNA and protein levels of
cyclin B1 and cyclin D1 were tested. We found that pio-
glitazone treatment and PAPRγ overexpression signifi-
cantly down-regulated both mRNA and protein levels of
cyclin B1 and cyclin D1. These results suggest that the
beneficial functions of the TZDs are mediated, at least in
part, by regulating the expression and transcription of
cyclin B and cyclin D.
Aside from the impact of proliferation of VSMCs on
the formation of atherosclerosis and restenosis, the
apoptosis of VSMC also plays an important role in these
processes. The pro-apoptotic effect of PPARγ in VSMCs
has been reported. Bruemmer’s group revealed that the
Oct-1 protein was regulated by the TZDs, which in turn
induced overexpression of the growth arrest and DNA
damage inducible protein 45(GADD45) gene, ultimately
leading to the apoptosis of VSMCs [40]. Other groups
have shown that pioglitazone also activated TGF (Trans-
forming Growth Factor)-β-smad2-GADD45 pathway
[41,42]. Pioglitazone induced apoptosis in VSMCs through
Smad2 phosphorylation [11]. Caspases are a family of
cysteine proteases that play important roles in apop-
tosis. Caspase 8 and caspase 9 are the two initiative cas-
pases involved in both extrinsic and intrinsic apoptotic
pathways, while caspase 3 is a terminal effector caspase
[43]. Bruedigam group showed that rosiglitazone stimu-
lated mineralization by induction of caspase-dependent
apoptosis [44]. Here, we found that pioglitazone treat-
ment and PPARγ overexpression induced activation of
caspase 8 and caspase 3/7, indicating that pioglitazone
induces VSMC apoptosis through the extrinsic caspase
pathway.
In summary, our study shows for the first time the regu-
latory pathways involved in the anti-proliferative effect of
pioglitazone in VSMCs. Pioglitazone treatment inhibits
proliferation of the VSMCs and induces VSMC apoptosis
in a PPARγ-dependent pathway. Down-regulation of cyc-
lin B1 and cyclin D1 and activation of caspase 8 and
caspase 3/7 may be one of the mechanisms by which
pioglitazone inhibits VSMC proliferation.
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